{"prompt": "['FLUAD vs Fluzone-HD', 'Version 5.0', 'September 25, 2018', '6.1', 'Influenza Hemagglutination Inhibition (HAI) Assay', '31', '7', 'STATISTICAL CONSIDERATIONS', '31', '7.1', 'Analysis Plan', '32', '7.1.1', 'Sample Size', '32', '7.1.2', 'Analysis Populations', '32', '7.1.3', 'Primary Objective 1', '33', '7.1.4', 'Primary Objective 2', '33', '7.1.5', 'Primary Objective 3', '33', '7.1.6', 'Secondary Objective 1', '34', '7.1.7', 'Secondary Objective 2', '34', '7.1.8', 'Secondary Objective 3', '35', '7.1.9', 'Sensitivity Analyses', '35', '7.1.10', 'Exploratory Objectives', '36', '7.2', 'Data Management', '36', '7.2.1 Research Electronic Data Capture (REDCap)', '36', '7.3', 'Role of the CDC Investigators in the Project', '37', '8', 'HUMAN SUBJECTS', '37', '8.1', 'Human Subjects Involvement, Characteristics, and Design', '37', '8.2', 'Sources of Material', '38', '8.3', 'Potential Risks and Benefits', '38', '8.4', 'Adequacy of Protection Against Risks', '38', '8.4.1', 'Protections against Risk', '39', '8.4.2', 'ClinicalTrials.gov Requirements', '39', '8.5', 'Human Subjects', '39', '8.5.1 Vulnerable Subjects Research', '39', 'REFERENCES', '41', 'APPENDIX', '43', 'Appendix A: Written Informed Consent', '44', 'Appendix B: Mini-Cog', '56', 'Appendix C: Rowland Universal Dementia Assessment Scale (RUDAS)', '59', 'Appendix D: Treatment Administration Record/Immediate Reactogenicity Assessment Form', '62', 'Appendix E: Patient Symptom Diary', '65', 'Appendix F: FACES Pain Scale', '73', 'Appendix G: Immune-Mediated Conditions', '75', 'Appendix H: Safety Monitoring Plan', '77', 'Appendix I: LLFDI-CAT', '80', 'Appendix J: EQ-5D-5L and VAS', '118', 'Appendix K: Vaccine Reaction Questionnaire', '121', 'Appendix L: Perceptions of the Vaccination Experience', '125', 'Appendix M: Recruitment Letter', '132', 'Appendix N: Flyer', '133', 'Appendix O: Phone Script', '135', '4']['FLUAD vs Fluzone-HD', 'Version 5.0', 'September 25, 2018', 'PROTOCOL SUMMARY', 'Title:', 'Safety and Immunogenicity of Adjuvanted versus High-Dose', 'Inactivated Influenza Vaccines in Older Adults', 'Phase:', 'Phase IV', 'Population:', '>880 community-dwelling adults >65 years of age who intend', 'to receive the inactivated influenza vaccine (IIV) during the', '2017-2018 (Year 1) or 2018-2019 (Year 2) influenza season.', 'Approximately 20% of the participants will be >80 years old.', 'Clinical Sites:', 'Three: Duke University (Lead); Boston Medical Center', \"(Contributing); Cincinnati Children's Hospital (Contributing\", 'Subcontractor)', 'Study Duration:', '24 months total', '18 months to recruit/enroll over two influenza seasons', '6 weeks participation for most subjects', 'Maximum of 6 months participation for a subset of', 'approximately 100 participants at Duke during 2017-', '2018 flu season', '4.5 months to perform analysis and laboratory assays', 'after the end of each flu season', 'A subset of 60 subjects from year 1 will be revaccinated', 'with same influenza vaccine product during the year 2', 'influenza season at Duke', 'Participant Duration:', '43 days for 780 participants', '181 days for approximately 100 participants at Duke for', 'longer term immunogenicity studies (Year 1 only)', 'Approximately 14 months for 60 participants in the', 'repeat vaccination sub-study (at Duke only)', 'Description of Study', 'Procedures:', 'This is a prospective, randomized, blinded clinical trial to', 'assess the safety and immunogenicity of adjuvanted', 'inactivated influenza vaccine (allV3) versus High-Dose', 'inactivated influenza vaccine (IIV3-HD) in subjects aged >65', 'years. Participants aged 65 to 79 years will be randomized', '(1:1) to receive either allV3 or IIV3-HD using a permuted block', 'randomization scheme stratified by Lead and Contributing', 'Site(s) for at least 704 subjects. A separate permuted block', 'will be allocated for at least 176 subjects who are age 80 years', 'or older, thus achieving an overall N>880.', 'Vaccine reactogenicity will be assessed for 8 days post-', '5']\n\n###\n\n", "completion": "END"}